Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Charite University, Berlin, Germany Schering-Plough |
---|---|
Information provided by: | Charite University, Berlin, Germany |
ClinicalTrials.gov Identifier: | NCT00622687 |
This study compared the efficacy of different dosages of long-term iloprost treatment on Raynaud's phenomenon, ulcer healing, skin thickening, and progression of internal organ sclerosis in systemic sclerosis (SSc).
Methods. 50 SSc patients were 1:1 randomised either for maximally tolerated dose up to 2 ng/kg body weight [bw] per minute or low dose (0.5 ng/kg bw per minute) intravenous iloprost administration, for six hours daily over 21 days. The effect on RP, ulcer healing, skin thickness, oesophagus function, lung involvement as assessed by lung function parameters FVC and DLCO, and side effects were measured. Conclusions. The efficacy of prolonged administration of iloprost is also achieved with low dose iloprost by long term treatment. The effects suggest a disease-modifying capability of iloprost, but further studies are needed to proof this hypothesis.
Condition | Intervention | Phase |
---|---|---|
Systemic Sclerosis |
Drug: iloprost Drug: iloprost low dose Drug: iloprost therapy up to 2 ng/kg x min |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment, Efficacy Study |
Official Title: | Comparision Between Maximally Tolerated Intravenous Iloprost Doses Versus Low-Dosed Iloprost for a 21-Day Treatment Course |
Enrollment: | 50 |
Study Start Date: | September 1997 |
Study Completion Date: | December 2007 |
Primary Completion Date: | December 2003 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Active Comparator
low dose iloprost therapy 0.5 ng/kg x min
|
Drug: iloprost low dose
0.5 ng/kg x min over 6 h per day for 21 consecutive days
Drug: iloprost therapy up to 2 ng/kg x min
starting therapy at doses of 0.5 ng/kg x min, increase the dose every two days for 0.5 ng/kg x min up to the maximally tolerated dose or to 2 ng/kg x min
|
B: Active Comparator
high-dose therapy
|
Drug: iloprost
0.5-2 ng/kg x min for 6hours a day for 21 consecutive days
Drug: iloprost therapy up to 2 ng/kg x min
starting therapy at doses of 0.5 ng/kg x min, increase the dose every two days for 0.5 ng/kg x min up to the maximally tolerated dose or to 2 ng/kg x min
|
50 SSc patients (23 patients with limited SSc; 15 patients with diffuse SSc, and 12 patients with overlap syndromes fulfilling the ACR criteria for systemic sclerosis) and suffering from severe Raynaud`s phenomenon were included into the study after written informed consent to participate in this study. Severe Raynaud`s phenomenon was defined by a high burden of disease, by trophic skin changes, or the presence of digital ulcers.
Patients suffering from SSc related RP and/or digital ulceration were randomized 1 : 1 to one of the following groups that received either high or low dose infusions of iloprost for 21 consecutive days given once or twice a year. High dose patients (n=25) started on 0.5ng per kg bw and min over 6 hours a day. Depending on the tolerability the dosages were increased in increments gradually every two days for 0.5 ng/kg x min. The maximum dose administered was 2.0ng/kg bw and min. Low dose patients (n=25) were permanently treated with 0.5ng/kg bw over 6 hours per day for 21 consecutive days.
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Participation in other studies during the last 4 weeks was also not allowed. For fertile women, a negative pregnancy test was required.
Germany | |
Charrité Universitätsmedizin | |
Berlin, Germany, 10117 |
Principal Investigator: | Gabriela Riemekasten, MD | Charité Universitätsmedizin Berlin |
Responsible Party: | Cahrité Universitätsmedizin ( Riemekasten, PD Dr. med. ) |
Study ID Numbers: | ILO-1998, Schering GmbH |
Study First Received: | February 14, 2008 |
Last Updated: | February 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00622687 History of Changes |
Health Authority: | Germany: Federal Ministry of Education and Research |
iloprost systemic sclerosis digital ulcers observational study randomized |
Iloprost Vasodilator Agents Skin Diseases Ulcer Connective Tissue Diseases Scleroderma |
Scleroderma, Diffuse Platelet Aggregation Inhibitors Sclerosis Scleroderma, Systemic Cardiovascular Agents |
Vasodilator Agents Skin Diseases Hematologic Agents Sclerosis Cardiovascular Agents Pharmacologic Actions Iloprost |
Pathologic Processes Therapeutic Uses Connective Tissue Diseases Scleroderma, Diffuse Scleroderma, Systemic Platelet Aggregation Inhibitors |